Timeline of critically ill 2019 SARS-CoV-2 cases after onset of illness: Intensive care data from Turkey Kritik 2019 SARS-CoV-2 hastalarında hastalık başlangıç anından itibaren zaman akış çizelgesi

Creative Commons License

Küçük A. O., Pehlivanlar Küçük M., Pehlivanlar A., Ayaydin Mürtezaoğlu S., Çoban K., Semerci T., ...More

Tuberkuloz ve Toraks, vol.70, no.1, pp.63-75, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.5578/tt.20229908
  • Journal Name: Tuberkuloz ve Toraks
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, CAB Abstracts, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.63-75
  • Keywords: COVID-19, Intensive care unit, mortality, SARS-CoV-2
  • Recep Tayyip Erdoğan University Affiliated: No


Introduction: This study aimed to evaluate the epidemiological, clinical, laboratory characteristics and treatment and clinical outcomes of severe COVID-19 cases from a 3rd degree intensive care unit in Turkey. Materials and Methods: The study was conducted in a level three, 16-bed COVID intensive care unit. The investigation was planned as a retrospective and observational study. Patients who were admitted with COVID-19 pneumonia and respiratory failure in the intensive care unit between March 2020 and March 2021 and followed up due to critical illness were evaluated. Results: A total of 213 patients that were admitted to the intensive care unit with the diagnosis of COVID-19 pneumonia were included in the study. Median age of the patients was 66 (IQR 56.5-74) years, and 134 (62.9%) were males. One hundred and sixty-six (77.9%) of the patients had at least one comorbidity. Patients were followed up mainly with invasive mechanical ventilation [104 (48.8%)] and high flow nasal cannula [67 (31.5%)]. Median number of days was 7 (IQR 4-10) and included the first symptom onset to intensive care admission. The time to intubation was 9 (IQR 4-15) days, and the median day to intensive care discharge was 16 (IQR 11-23). After the symptoms started, first tocilizumab 9 (IQR 5-11) and pulse steroid treatment 8 (IQR 3-11) were found to be close to each other. In total, 95 (44.6%) of the 213 patients died. Conclusion: SARS-CoV-2 associated viral disease can progress after simple symptoms to hospital admission in a median of four days and to intensive care admission requiring intubation in a median of nine days. We believe that a better understanding of the clinical course of COVID-19 and its change between centers can be revealed through sharing information from different countries and centers.